Grant: CIHR Fellowship
Direct Payment
$150,000.00
Tumour-stroma interactions during breast-to-brain metastasis
EF 2012-13
Résumé
Breast cancer affects 1 in 9 Canadian women. The leading cause of death from breast cancer is when it spreads to a distant organ site (called "metastasis"). Metastasis of breast cancer to the brain is a detrimental event during disease progression, as there are currently no effective therapeutic options for treating this stage of disease at this particular secondary location.
Two important components of cancer are: (1) the tumour, and (2) the tumour's environment. A therapy that kills the tumour, and locally disrupts the environment so that it is unfavourable for tumour growth will likely optimize efficacy of treatment.
Recently, we have identified 3 factors that are important for breast cancer to spread to the brain. These factors are called Cathepsin C, Cathepsin L, and Cystatin 3. Two of these factors are specific to the tumour, and the third is specific to the tumour's environment. In patients, we have found that each of these factors correlates with increased brain metastasis and poor overall survival.
Experimental Plan and Hypotheses: By interfering with Cathepsin C, Cathepsin L, and/or Cystatin 3, we hope to block the ability of breast tumours to spread to the brain. Targeting these three factors will not only harm the tumour cells directly, but will also alter the environment in the brain so that it cannot support tumour growth.
One of the most valuable aspects of this project is that we have access to patient tissue sets that include a sample of (1) normal breast, (2) breast tumours, and (3) brain metastasis. Importantly, each set (1-3) is matched to a single patient, and we have sets from 60 patients in total (these are called "patient-matched" samples). This is extremely valuable for research, since it is extremely rare to have a large number of patient-matched tissue. Within each individual patient, we can determine how the normal breast tissue changed to become cancerous, and how the breast tumour changed to support brain metastasis
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
269570
Name
Quail Daniela
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Tumour-stroma interactions during breast-to-brain metastasis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bone Marrow-Derived Cells; Brain Metastasis; Breast Cancer; Cystatins; Cysteine Cathepsins; Epithelial Cells; Microenvironment; Proteolytic Networks; Stromal Cells
Abstract
Breast cancer affects 1 in 9 Canadian women. The leading cause of death from breast cancer is when it spreads to a distant organ site (called "metastasis"). Metastasis of breast cancer to the brain is a detrimental event during disease progression, as there are currently no effective therapeutic options for treating this stage of disease at this particular secondary location.
Two important components of cancer are: (1) the tumour, and (2) the tumour's environment. A therapy that kills the tumour, and locally disrupts the environment so that it is unfavourable for tumour growth will likely optimize efficacy of treatment.
Recently, we have identified 3 factors that are important for breast cancer to spread to the brain. These factors are called Cathepsin C, Cathepsin L, and Cystatin 3. Two of these factors are specific to the tumour, and the third is specific to the tumour's environment. In patients, we have found that each of these factors correlates with increased brain metastasis and poor overall survival.
Experimental Plan and Hypotheses: By interfering with Cathepsin C, Cathepsin L, and/or Cystatin 3, we hope to block the ability of breast tumours to spread to the brain. Targeting these three factors will not only harm the tumour cells directly, but will also alter the environment in the brain so that it cannot support tumour growth.
One of the most valuable aspects of this project is that we have access to patient tissue sets that include a sample of (1) normal breast, (2) breast tumours, and (3) brain metastasis. Importantly, each set (1-3) is matched to a single patient, and we have sets from 60 patients in total (these are called "patient-matched" samples). This is extremely valuable for research, since it is extremely rare to have a large number of patient-matched tissue. Within each individual patient, we can determine how the normal breast tissue changed to become cancerous, and how the breast tumour changed to support brain metastasis
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Quail, Daniela
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~